Recently, several international clinical trials have established the therapeutic efficacy of second-generation hormone therapy in prostate cancer, including abiraterone as an androgen synthesis inhibitor and enzalutamide as an androgen receptor (AR) antagonist. This evidence concerns the gene AR and prostate cancer.